- Our Company
- News & Events
- Contact Us
September marks Prostate Cancer Awareness Month. Check out this study (https://jitc.bmj.com/content/8/2/e001065) which concluded that the use of a well-validated cfDNA NGS liquid biopsy such as the Guardant360®️ test to identify metastatic prostate cancer patients with MSI-H is feasible in clinical practice and may overcome the obstacles associated with prostate cancer tumor tissue for timely genomic assessment.
Speak to your doctor today about comprehensive genomic testing with a simple blood draw. Visit us at https://www.guardanthealthamea.com/resources/ to find out how the Guardant360 test can help to guide treatment decisions for patients with advanced stage prostate cancer.
Reference: Barata P, Agarwal N, Nussenzveig R, et alClinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNAJournal for ImmunoTherapy of Cancer 2020;8:e001065. doi: 10.1136/jitc-2020-001065